Capricor Therapeutics, Inc. $CAPR Shares Purchased by Wellington Management Group LLP

Key Points

• Wellington Management Group LLP increased its stake in Capricor Therapeutics by 170.3%, owning 110,731 shares after acquiring an additional 69,772 shares during the first quarter.
• Capricor Therapeutics has shown strong interest from institutional investors, with 21.68% of its stock owned by large financial organizations.
• Despite a recent drop in earnings, analysts generally hold a positive outlook on Capricor, with an average rating of "Buy" and a target price of $22.56.

Wellington Management Group LLP lifted its position in Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) by 170.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 110,731 shares of the biotechnology company's stock after buying an additional 69,772 shares during the quarter. Wellington Management Group LLP owned approximately 0.24% of Capricor Therapeutics worth $1,051,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Citizens Financial Group Inc. RI bought a new stake in shares of Capricor Therapeutics during the 1st quarter valued at $95,000. ProShare Advisors LLC bought a new stake in shares of Capricor Therapeutics in the fourth quarter valued at about $142,000. Voya Investment Management LLC acquired a new position in shares of Capricor Therapeutics during the fourth quarter valued at about $150,000. Arizona State Retirement System purchased a new stake in Capricor Therapeutics in the first quarter valued at approximately $111,000. Finally, The Manufacturers Life Insurance Company boosted its position in Capricor Therapeutics by 22.4% in the 4th quarter. The Manufacturers Life Insurance Company now owns 12,919 shares of the biotechnology company's stock worth $178,000 after purchasing an additional 2,361 shares in the last quarter. Institutional investors own 21.68% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on CAPR. HC Wainwright reduced their price objective on shares of Capricor Therapeutics from $77.00 to $24.00 and set a "buy" rating on the stock in a report on Friday, July 11th. Piper Sandler reaffirmed an "overweight" rating and set a $20.00 price target on shares of Capricor Therapeutics in a research note on Friday, July 11th. Alliance Global Partners reaffirmed a "buy" rating on shares of Capricor Therapeutics in a report on Monday, July 14th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $30.00 target price on shares of Capricor Therapeutics in a research note on Wednesday, May 14th. Finally, Roth Capital lowered their target price on Capricor Therapeutics from $31.00 to $12.00 and set a "buy" rating on the stock in a report on Monday, July 14th. One research analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $22.56.

Capricor Therapeutics Stock Up 3.4%

Shares of NASDAQ CAPR traded up $0.20 during midday trading on Friday, hitting $6.14. 259,576 shares of the company's stock were exchanged, compared to its average volume of 1,962,983. The company's 50 day moving average price is $7.84 and its 200 day moving average price is $10.20. The firm has a market capitalization of $280.72 million, a PE ratio of -3.68 and a beta of 0.73. Capricor Therapeutics, Inc. has a 12 month low of $3.98 and a 12 month high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last announced its earnings results on Monday, August 11th. The biotechnology company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.09). Capricor Therapeutics had a negative net margin of 181.71% and a negative return on equity of 62.71%. On average, equities research analysts anticipate that Capricor Therapeutics, Inc. will post -1.21 EPS for the current year.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.